APAC Healthcare Weekly (December 21)–Fosun Pharma, Hansoh, Daiichi Sankyo, Takeda, Hanmi, Max Health
Fosun Pharma is acquiring 53% stake in Green Valley. Hansoh inked exclusive license agreement with Glenmark Pharma. Daiichi Sankyo’s Enhertu got...
325 Views
Pre-IPO Cloudbreak Pharma (PHIP Updates) - Some Points Worth the Attention
Low diagnosis/treatment rate for pterygium may impact willingness to pay for CBT-001. Commercialization outlook is highly uncertain due to...
606 Views
Cloudbreak (拨康视云) Pre-IPO: PHIP Updates
Cloudbreak re-files for Hong Kong listing, facing delays and downward revisions in prospects with negative peer performance readthrough.
415 Views
Cloudbreak 拨康视云 IPO: Negative Readthrough from Underperforming Market Leader
Cloudbreak re-files for Hong Kong listing to raise $100M, core product progress on track but delays in other products, negative readthrough from...
612 Views
Hong Kong: IPO SPOTLIGHT - OVERVIEW 2025
Hong Kong is the top global destination for IPOs in 2025, with over HK $280 billion raised so far. Large scale A+H dual listings have surged this...
654 Views